Lv3
386 积分 2026-01-06 加入
P3.13.34 Tarlatamab Efficacy and Safety in Chinese Patients with Advanced Small Cell Lung Cancer: Phase 2 DeLLphi-307
28天前
已完结
2757O Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study
1个月前
已关闭
Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer
2个月前
已完结
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
2个月前
已完结
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
2个月前
已完结
Consensus on cytokine release syndrome (CRS) monitoring practices: A Delphi approach
4个月前
已关闭
Cytokine release syndrome: Who is at risk and how to treat
4个月前
已完结
Management Principles Associated With Cytokine Release Syndrome
4个月前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
6个月前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
6个月前
已完结
皖公网安备34019202002308
